<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of familial Mediterranean fever</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of familial Mediterranean fever</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of familial Mediterranean fever</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eldad Ben-Chetrit, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Pisetsky, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 23, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disorder characterized by recurrent bouts of fever and serosal inflammation. Its major complication is the insidious development of secondary (AA) amyloidosis with eventual renal failure in uncontrolled patients. This topic will review the management of FMF. The epidemiology, genetics, pathophysiology, and clinical manifestations of FMF and an overview of periodic fever syndromes and other autoinflammatory diseases can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2634.html" rel="external">"Familial Mediterranean fever: Epidemiology, genetics, and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/2635.html" rel="external">"Clinical manifestations and diagnosis of familial Mediterranean fever"</a> and  <a class="medical medical_review" href="/z/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview"</a>.)</p><p class="headingAnchor" id="H636227989"><span class="h1">INITIAL MANAGEMENT</span><span class="headingEndMark"> — </span>The goals of therapy for familial Mediterranean fever (FMF) are to prevent acute attacks and minimize subclinical inflammation in between attacks, and to prevent the development and progression of amyloidosis. Initial treatment of FMF is with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>.</p><p class="headingAnchor" id="H4258833468"><span class="h2">Colchicine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> is primarily effective as a prophylactic treatment for the FMF attacks. It is recommended in all patients regardless of the frequency and intensity of attacks. Use of intermittent high-dose colchicine only for treatment of acute attacks of FMF is not recommended since it does not protect from the development of amyloidosis resulting from low-grade inflammation that can occur during asymptomatic intervals [<a href="#rid1">1-5</a>].</p><p class="headingAnchor" id="H1903639870"><span class="h3">Dosing and administration</span><span class="headingEndMark"> — </span>Treatment with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> should be started as soon as a diagnosis of FMF is established and should be continued indefinitely. However, in rare cases of heterozygous FMF patients who are asymptomatic for several (more than five) years and do not display elevated acute phase reactants, it may be possible to discontinue colchicine [<a href="#rid6">6,7</a>]. In one study, 59 children with FMF discontinued colchicine and were followed for an average of 5±3.05 years [<a href="#rid8">8</a>]. During the follow-up period, 11 (20 percent) patients had an attack (mostly fever) and required renewal of colchicine treatment. Myalgia and arthritis prior to colchicine cessation were more common among children who required restart of colchicine, whereas a longer attack-free period prior to colchicine discontinuation predicted successful colchicine cessation.</p><p>We recommend the following starting dose of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For children &lt;5 years of age, ≤0.5 mg/day (≤0.6 mg/day in case tablets contain 0.6 mg).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children 5 to 10 years of age, 0.5 to 1 mg/day (0.6 to 1.2 mg/day in case tablets contain 0.6 mg).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children &gt;10 years of age and adults, 1 to 1.5 mg/day (1.2 to 1.8 mg/day in case tablets contain 0.6 mg).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with preexisting complications (eg, renal amyloidosis) or greater disease activity (ie, high frequency of attacks, long duration of each attack, involvement of multiple sites during the attack, and joint involvement) [<a href="#rid10">10</a>], higher initial doses (up to 2 mg/day) are needed, provided that kidney and liver function are normal [<a href="#rid11">11-13</a>].</p><p></p><p>Adherence with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> is higher with once-daily dosing, and its efficacy is the same as with splitting the dose into two divided daily doses [<a href="#rid14">14</a>]. We do not split the colchicine dose unless the patient does not tolerate once-daily dosing due to side effects, which are most commonly gastrointestinal. We generally start with a lower dose and increase the dose by 0.5 to 0.6 mg according to the patient’s response and tolerance without exceeding the maximum recommended daily dose of colchicine, which is 2 mg for children under 12 years and 3 mg for adults. Dose adjustment of colchicine is necessary in patients with renal or liver impairment. Dose adjustments are found in the Lexicomp drug information topic within UpToDate.</p><p>An oral solution of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> (0.6 mg/5 mL) is also available in some areas for gout prophylaxis and may be used off-label in FMF patients who have difficulty swallowing pills or who require small dose adjustments [<a href="#rid15">15</a>]. Patients or caregivers must be reliably capable of using an oral measuring syringe with mL markings.</p><p>Administering <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> only during an acute FMF attack or increasing its dose during the acute attack usually has no impact on the attack symptoms. In addition, high-dose colchicine is associated with significant side effects. We do not administer colchicine intravenously because of the risk of serious adverse effects. </p><p class="headingAnchor" id="H1183556811"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>Following initiation of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, patients with FMF should be followed closely for three to six months to observe its therapeutic effect on attack frequency and severity.</p><p>Once the appropriate <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> dose has been established, patients should be monitored for toxicity and response to therapy approximately every six months. Laboratory testing for colchicine toxicity includes a complete blood count (CBC) to assess for leukopenia. For monitoring disease response, we check erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and, when available, serum amyloid A (SAA). We also check the urine for proteinuria, which may be the first sign of renal amyloidosis. We check liver and kidney function tests annually to ensure that no modification of the colchicine dose is required. We do not routinely monitor muscle enzymes. Colchicine-induced myopathy occurs either when the patient has kidney failure (elevated creatinine) or when colchicine is given concomitantly with other medications inhibiting cytochrome P450 3A4 and/or the glycoprotein 1 pump. In these selected cases, we reduce the dose of colchicine and monitor muscle enzymes (creatine phosphokinase [CPK], lactate dehydrogenase [LDH]).</p><p class="headingAnchor" id="H2810963765"><span class="h3">Mechanism of action</span><span class="headingEndMark"> — </span>The pathophysiology of FMF involves the recruitment and activation of neutrophils at serosal surfaces. <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> affects the motility of neutrophils by reducing their deformability and elasticity by tubulin disruption. These properties are crucial for their extravasation in response to inflammatory stimuli [<a href="#rid16">16,17</a>]. Additional mechanisms include various inhibitory effects on macrophages including the inhibition of NALP3 and pyrin inflammasomes and stimulation of dendritic cell maturation and antigen presentation [<a href="#rid17">17,18</a>]. The ability of colchicine to cause mitotic arrest is unlikely to play a role in its therapeutic action because the dose required to suppress mitosis is in considerable excess of that used for FMF. (See  <a class="medical medical_review" href="/z/d/html/2634.html" rel="external">"Familial Mediterranean fever: Epidemiology, genetics, and pathogenesis"</a>.)</p><p class="headingAnchor" id="H825246952"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> has demonstrated efficacy in preventing acute inflammatory episodes as well as preventing or slowing the progression toward amyloidosis.</p><p class="headingAnchor" id="H1759409628"><span class="h4">Decreasing the frequency of attacks</span><span class="headingEndMark"> — </span>The efficacy of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> in decreasing the frequency of attacks in FMF has been demonstrated in three double-blind, placebo-controlled trials [<a href="#rid2">2-4</a>]. In one such trial that included 43 patients with FMF, treatment with colchicine resulted in a significant reduction of the number of attacks as compared with placebo (29 versus 178). Another trial showed that patients treated with colchicine are also more likely to have milder attacks as compared with placebo (70 versus 25 percent) [<a href="#rid3">3</a>].</p><p>In the long term, up to 40 percent of the patients treated with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> had partial remission, approximately 5 percent were non-responders, and 2 to 5 percent did not tolerate the drug, mainly due to gastrointestinal side effects [<a href="#rid19">19</a>]. (See <a class="local">'Safety'</a> below.)</p><p class="headingAnchor" id="H3832307519"><span class="h4">Prevention of amyloidosis</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a>, as preventive therapy, can markedly reduce the incidence of clinical renal disease and can prevent additional deterioration of renal function in patients with mild proteinuria due to amyloidosis [<a href="#rid20">20,21</a>].</p><p>Among FMF patients with the nephrotic syndrome, prevention of disease progression and a reduction in protein excretion can be achieved. However, a higher <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> dose of 1.5 to 2.0 mg/day appears to be required, and therapy should be instituted before the plasma creatinine concentration reaches 1.5 mg/dL (132 micromol/L) [<a href="#rid11">11,12</a>]. Protein excretion in responders can be reduced to below 1 to 2 g/day with this regimen; the benefit is gradual, occurring over a one- to two-year period [<a href="#rid11">11</a>]. In one study that included 1070 patients with FMF, among 960 patients who initially had no evidence of amyloidosis, the rate of development of proteinuria was 1.7 percent after 11 years in the adherent patients. By contrast, proteinuria developed in 49 percent of nonadherent patients after nine years [<a href="#rid20">20</a>]. Among 86 patients who already had non-nephrotic proteinuria prior to therapy, colchicine led to resolution of proteinuria in five and stabilization in 68; 13 had progressive disease.</p><p><a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> is not likely to be effective in patients who already have chronic renal failure, since irreversible glomerular injury is probably present [<a href="#rid11">11,12</a>]. However, it can prevent recurrent disease (as manifested by proteinuria) in the transplant kidney [<a href="#rid13">13</a>]. The optimal colchicine dose in this setting is 1.5 to 2.0 mg/day; lower doses are less predictably effective. A report of three patients with amyloidosis in native kidneys described improvement in proteinuria and the plasma creatinine level, and reduction in the frequency of peritonitis attacks with the addition of <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> to colchicine, although the mechanism of the azathioprine effect is unclear [<a href="#rid22">22</a>]. Anecdotal reports suggest that, in patients with established secondary (AA) amyloidosis, anti-interleukin (IL) 1 treatment can also reverse proteinuria [<a href="#rid23">23</a>]. However, in a study from Turkey including 39 transplant recipients due to end-stage kidney disease from FMF-induced secondary amyloidosis, de novo amyloid accumulation was observed during the treatment with IL-1 antagonists [<a href="#rid24">24</a>]. (See <a class="local">'Interleukin 1 inhibition'</a> below.)</p><p class="headingAnchor" id="H3028512520"><span class="h3">Safety</span><span class="headingEndMark"> — </span>At doses of 1 to 2 mg/day, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> is safe even when given continually over decades, provided that the kidney and liver functions are intact. Side effects, most commonly gastrointestinal (eg, diarrhea, nausea, vomiting), are uncommon at low doses (0.5 to 1.2 mg per day), even when given continuously over years. Less common (&lt;1 percent) side effects include bone marrow suppression, hepatotoxicity, and myotoxicity. Chronic renal insufficiency leading to increased colchicine levels is a major risk factor for side effects. In addition, colchicine has drug interactions and altered metabolism in certain patient populations. In particular, concomitant administration of drugs metabolized by cytochrome P450 3A4 or affecting the glycoprotein 1 pump (ATP-binding cassette sub-family B member 1 [ABCB1]) has been associated with a greater risk of colchicine toxicity due to the resulting increased serum and tissue concentration of colchicine  (<a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 1</a>) [<a href="#rid25">25</a>]. (For additional information on drug interactions, use the <a class="external" href="/drug-interactions">drug interactions program</a> provided by UpToDate.) </p><p>Concerns about gonadal toxicity in males have been raised. One study found either azoospermia or abnormal sperm penetration in up to 20 percent of males treated with long-term <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> therapy [<a href="#rid26">26</a>]; however, a second smaller study found no change in sperm count over six months of therapy [<a href="#rid27">27</a>]. Our experience shows that this complication is rare and in most cases reversible following cessation of colchicine. Azoospermia is more common among Behçet syndrome patients treated with colchicine than in FMF patients [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H1140308894"><span class="h1">SUBSEQUENT MANAGEMENT</span><span class="headingEndMark"> — </span>Despite treatment with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, some patients continue to have either symptoms of familial Mediterranean fever (FMF) or elevated acute phase reactants (erythrocyte sedimentation rate [ESR], C-reactive protein [CRP]) between attacks.</p><p class="headingAnchor" id="H3760771913"><span class="h2">Reassessment</span><span class="headingEndMark"> — </span>Patients with continued symptoms while on <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> should be carefully reassessed, paying specific attention to the type of persistent symptoms, the degree to which symptoms have improved or worsened, and adherence with medications [<a href="#rid29">29</a>]. Levels of acute phase reactants should also be monitored.</p><p>Patients who fail to respond to <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> fall into one of the following categories:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients whose symptoms are not due to FMF</strong> – These patients may have other hereditary autoinflammatory diseases that may mimic FMF: tumor necrosis factor (TNF) receptor-1 associated periodic syndrome (TRAPS); periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA); and mevalonate kinase deficiency (MKD, hyperimmunoglobulin D syndrome), none of which usually respond to this drug. Some patients with PFAPA, however, may respond to <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who are nonadherent or incompletely adherent with therapy</strong> – Adherence with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> therapy must be confirmed [<a href="#rid31">31</a>]. In one study, more than 40 percent of the patients with apparent colchicine-resistant FMF (crFMF) actually had poor adherence [<a href="#rid32">32</a>]. Patients with poor adherence related to side effects may benefit from divided doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colchicine-resistant FMF</strong> – Patients with FMF who still experience frequent attacks despite the maximal tolerable dose of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> (up to 3 mg daily in adults and 2 mg in children) are considered to have crFMF. In clinical practice, we do not use a specific threshold for defining crFMF, and it is largely based on poor patient tolerance of attacks rather than their frequency. Consensus recommendations for the management of FMF have defined crFMF as the occurrence of one or more attacks each month despite receiving the maximally tolerated dose for at least six months [<a href="#rid9">9</a>]. A revised definition of crFMF suggests that for a patient receiving the maximum tolerated dose of colchicine, resistance to colchicine is defined as ongoing disease activity (as reflected by either recurrent clinical attacks [average one or more attacks per month over a three-month period] or persistently elevated CRP or serum amyloid A [SAA] in between attacks [depending on which is available locally]), in the absence of any other plausible explanation [<a href="#rid33">33</a>]. Patients with elevated acute phase reactants (any value above normal range in at least two successive tests) between attacks despite maximal or tolerable dose of colchicine are considered crFMF because of their risk of developing amyloidosis.</p><p></p><p>The characteristics of patients with FMF who are truly <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> non-responders are incompletely understood. One report compared 59 patients who did not respond to colchicine with 51 responders [<a href="#rid34">34</a>]. Non-responders tended to be from lower socioeconomic backgrounds, have less education, and have a more severe form of disease. In addition, they had a statistically lower concentration of colchicine in mononuclear cells. The authors speculated that non-responders may be genetically predisposed to have a lower colchicine concentrating ability. One factor might be poorer gastrointestinal absorption of the drug, which has a wide range of absorption (24 to 88 percent) after oral ingestion [<a href="#rid35">35</a>]. In addition, colchicine activity may be related to its concentration within leukocytes rather than plasma levels [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H3606819316"><span class="h2">Colchicine resistance or intolerance</span><span class="headingEndMark"> — </span>Approximately 5 percent of FMF patients are non-responders, and 2 to 5 percent do not tolerate the drug mainly due to gastrointestinal side effects [<a href="#rid19">19</a>]. Interleukin (IL) 1 inhibition is the preferred second-line therapy for these patients. Anecdotal reports suggest that IL-1 inhibition has a beneficial effect on amyloidosis, but more data are needed to confirm this observation. Thus, for patients who are colchicine-resistant and on IL-1 inhibitors, we give concomitant <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> at a tolerable dose (or approximately 1.5 to 2 mg daily) in order to prevent amyloidosis. In patients who do not respond to IL-1 inhibitors, we try therapy with TNF inhibitors (eg, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>) or <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>.</p><p class="headingAnchor" id="H3231174827"><span class="h3">Interleukin 1 inhibition</span><span class="headingEndMark"> — </span>Increasing data suggest that IL-1 inhibition seems to be a relatively safe and effective alternative for patients with FMF who do not respond to or cannot tolerate <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>. The choice of IL-1 inhibitor is based on a combination of factors including regulatory or insurance requirements, route of administration, and cost. <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">Canakinumab</a> is generally preferred due to its efficacy and convenience since it is given as a subcutaneous injection every four to eight weeks. Moreover, data from two observational studies suggest that canakinumab may be beneficial following failure of or intolerance to <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> [<a href="#rid37">37,38</a>]. The most common side effects reported were site injection reaction and slightly increased mild infections in patients treated with anakinra and canakinumab, respectively.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">Canakinumab</a> – Canakinumab is a human immunoglobulin G (IgG) antibody directed against IL-1-beta. Several studies have demonstrated efficacy of canakinumab in patients with crFMF [<a href="#rid39">39-42</a>]. In a systematic review of eight studies that included 40 patients with crFMF, rates of complete and partial response to canakinumab were 68 and 32 percent, respectively [<a href="#rid41">41</a>]. One patient treated with canakinumab had secondary (AA) amyloidosis, and a significant decrease in urinary protein excretion was recorded after canakinumab. Seven patients had previously been treated with <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>. In four patients, anakinra was discontinued due of side effects. None of these patients had side effects while on canakinumab. In two patients in whom anakinra was unsuccessful in controlling inflammation, treatment with canakinumab resulted in a complete response. In an industry-sponsored randomized trial which included 63 genetically confirmed FMF patients who were colchicine-resistant, 61 versus 6 percent of patients receiving monthly 150 mg canakinumab or placebo, respectively, had a complete response (defined as resolution of flare and no flare) at 16 weeks [<a href="#rid42">42</a>]. Raising the dose to 300 mg canakinumab monthly increased the rate of complete response to 71 percent. After 16 weeks, a prolonged dosing interval of canakinumab (every eight weeks) maintained disease control in 46 percent of patients with crFMF. Three serious infections (one each of cellulitis, pelvic abscess, and pharyngotonsillitis) were reported in two crFMF patients receiving canakinumab within the first 16 weeks. However, no new safety findings or deaths were reported in canakinumab-treated patients throughout the 40-week study. In an extension of this study which included 60 patients who were followed for 72 weeks, 35 out of 60 (58.3 percent) patients experienced no flares, and 23 out of 60 (38.3 percent) had 1 flare, as compared with a median of 17.5 flares per year reported at baseline [<a href="#rid43">43</a>]. Median CRP concentrations were always in the normal range, while median SAA concentrations remained over the limit of normal (10 mg/L) but under the 30 mg/L threshold. There were no new or unexpected adverse events.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">Anakinra</a> – Anakinra is a recombinant version of the IL-1 receptor antagonist. A systematic review of IL-1 inhibitors for FMF including 64 patients from case reports or series treated with anakinra found a complete response to therapy in 77 percent of patients [<a href="#rid41">41</a>]. A decrease in attack frequency and inflammation was noted in an additional 19 percent of patients. Three patients had no clinical response to anakinra. The only randomized trial to evaluate the use of anakinra in crFMF patients included 24 patients from a single center who received daily injections of either anakinra or placebo and were followed for four months [<a href="#rid44">44</a>]. Patients in the anakinra group had significantly fewer attacks per month and experienced a significant improvement in quality of life. There were no severe adverse events observed with anakinra. Local injection site reaction was the most common adverse event. The benefits of anakinra have been supported by larger subsequent observational studies [<a href="#rid45">45,46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9483" href="/z/d/drug information/9483.html" rel="external">Rilonacept</a> – Rilonacept is a dimeric fusion protein consisting of the extracellular portions of the human IL-1 receptor and the Fc region of human IgG1 that binds and neutralizes IL-1. In a small, randomized, double-blind study, 14 patients with FMF with one or more attacks per month were enrolled [<a href="#rid47">47</a>]. Each patient was scheduled to receive one of four treatment sequences that included two three-month courses of rilonacept, 2.2 mg/kg (maximum, 160 mg) by weekly subcutaneous injection, and two three-month courses of placebo. Among 12 participants who completed two or more treatment courses, the rilonacept-placebo attack risk ratio was 0.59. The median number of attacks per month was 0.77, and there were more treatment courses of rilonacept without attacks than with placebo. However, the duration of attacks did not differ between placebo and rilonacept. Thus, rilonacept reduces the frequency but not duration of FMF attacks and seems to be a treatment option for patients with colchicine-resistant or intolerant FMF.</p><p></p><p class="headingAnchor" id="H512886115"><span class="h3">Other agents</span><span class="headingEndMark"> — </span>A few crFMF patients have shown responsiveness to <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, and <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> [<a href="#rid48">48-52</a>]. However, the true efficacy and safety of treatment with these agents remains uncertain because of the paucity of reports and absence of controlled trials. Several studies have also described a potential role for interferon alfa in aborting or preventing attacks [<a href="#rid53">53-56</a>], but this is hardly used given the efficacy and tolerability of the interleukin-1 inhibitors.</p><p class="headingAnchor" id="H79502648"><span class="h1">MANAGEMENT OF SPECIFIC FEATURES</span><span class="headingEndMark"> — </span>Some patients with familial Mediterranean fever (FMF) may develop other related features that are not responsive to <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> or interleukin (IL) 1 inhibitors and require additional therapy.</p><p class="headingAnchor" id="H2820147233"><span class="h2">Chronic arthritis</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> is not always an effective treatment for chronic arthritis associated with FMF, and patients may require nonbiologic or biologic disease-modifying antirheumatic drugs (DMARDs) [<a href="#rid57">57,58</a>].<strong> </strong>In FMF patients with spondyloarthropathy (usually human leukocyte antigen [HLA]-B27-negative sacroiliitis), we may start with <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> and/or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, and if there is no response we add anti-tumor necrosis factor (TNF) agents. (See  <a class="medical medical_review" href="/z/d/html/2635.html" rel="external">"Clinical manifestations and diagnosis of familial Mediterranean fever", section on 'Joint pain'</a>.)</p><p class="headingAnchor" id="H2896697044"><span class="h2">Protracted febrile myalgia</span><span class="headingEndMark"> — </span>Patients with protracted febrile myalgia typically require treatment of glucocorticoids for relief of symptoms. Usually we start with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg daily for one to two weeks and then decrease the dose gradually over four to eight weeks. (See  <a class="medical medical_review" href="/z/d/html/2635.html" rel="external">"Clinical manifestations and diagnosis of familial Mediterranean fever", section on 'Other manifestations'</a>.)</p><p class="headingAnchor" id="H2698807684"><span class="h2">Exertional myalgia</span><span class="headingEndMark"> — </span>Exercise-induced myalgia (mainly in the calves) improves with resting or treatment with nonsteroidal antiinflammatory drugs (NSAIDs). NSAIDs may be given once the patient experiences muscle pain, and the symptoms typically resolve with a single dose. We do not advise prophylactic NSAID use prior to exercise. Any NSAID may be used, and in some cases <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> is effective too. (See  <a class="medical medical_review" href="/z/d/html/2635.html" rel="external">"Clinical manifestations and diagnosis of familial Mediterranean fever", section on 'Other manifestations'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H12"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>The benefits of continued <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> therapy through pregnancy outweigh any risks to the fetus as well as prevent painful symptomatic attacks for the mother. Thus, continued use of colchicine is recommended for pregnant patients with familial Mediterranean fever (FMF).</p><p>FMF has been associated with a higher-than-normal rate of miscarriage and infertility even in the absence of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>. One study of women on long-term colchicine therapy found a 25 percent miscarriage rate and a 36 percent infertility rate [<a href="#rid59">59</a>]. However, these rates were comparable to those reported in women with FMF prior to the introduction of colchicine therapy. The same study found that all the infants born to mothers with FMF on colchicine were healthy. Furthermore, colchicine therapy has never been associated with an increased risk of fetal abnormalities. Four large studies involving a total of more than 1000 colchicine-exposed pregnancies have shown no evidence of an increase in cytogenetic or congenital abnormalities and suggest that colchicine treatment does not confer a risk of preterm delivery [<a href="#rid60">60-63</a>].</p><p class="headingAnchor" id="H3744576345"><span class="h2">Breastfeeding</span><span class="headingEndMark"> — </span>Nursing is safe in women with FMF who continue to take <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> [<a href="#rid64">64</a>]. One report serially measured the colchicine concentrations in serum and breast milk in four women [<a href="#rid65">65</a>]. The concentrations in breast milk were low (1.9 to 8.6 ng/mL) and similar to those in serum; the low values reflect extensive peripheral tissue binding of colchicine.</p><p class="headingAnchor" id="H1114241616"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/121582.html" rel="external">"Society guideline links: Familial Mediterranean fever"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The goals of therapy for familial Mediterranean fever (FMF) are to prevent acute attacks and minimize subclinical inflammation in between attacks, and to prevent the development and progression of amyloidosis. For all patients with FMF, we recommend initial treatment with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). The maximum recommended daily dose of colchicine is 2 mg for children under 12 years and 3 mg for adults. (See <a class="local">'Colchicine'</a> above and <a class="local">'Efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After initiation of <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, patients with FMF should be followed closely for three to six months to observe its therapeutic effect on attack frequency and severity. Laboratory testing for colchicine toxicity includes a complete blood count (CBC) to assess for leukopenia. For monitoring disease response, we check erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and, when available, serum amyloid A (SAA). We also check the urine for proteinuria, which may be the first sign of renal amyloidosis. We check liver and kidney function tests annually to ensure that no modification of the colchicine dose is required. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At doses of 1 to 2 mg/day, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> is safe even when given continually over decades, provided that the liver and kidney functions are normal. Side effects, most commonly gastrointestinal (eg, diarrhea, nausea, vomiting), are uncommon at low doses (0.5 to 1.2 mg per day). Less common (&lt;1 percent) side effects include bone marrow suppression, hepatotoxicity, and myotoxicity. Chronic renal insufficiency or liver cirrhosis leading to increased colchicine levels is a major risk factor for side effects. Colchicine also has drug interactions and altered metabolism in certain patient populations. (See <a class="local">'Safety'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with continued symptoms despite treatment with <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> should be carefully reassessed, paying specific attention to the type of persistent symptoms, the degree to which symptoms have improved or worsened, and adherence with medications. Patient who fail to respond to therapy with colchicine may have an alternative diagnosis (eg, another hereditary autoinflammatory disease), may be nonadherent or incompletely adherent, or may be colchicine-resistant. (See <a class="local">'Reassessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 5 percent of FMF patients are colchicine-resistant, and 2 to 5 percent do not tolerate the drug mainly due to gastrointestinal side effects. Interleukin (IL) 1 inhibition is the preferred second-line therapy for these patients. It is unknown whether IL-1 inhibitors have a beneficial effect on amyloidosis. Thus, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> should be continued in FMF patients who receive such treatment. (See <a class="local">'Colchicine resistance or intolerance'</a> above and <a class="local">'Interleukin 1 inhibition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients with FMF may develop other related features that are not responsive to <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> or IL-1 inhibitors and require additional therapy. These features include a chronic form of arthritis, protracted febrile myalgia, and exertional myalgia. (See <a class="local">'Chronic arthritis'</a> above and <a class="local">'Protracted febrile myalgia'</a> above and <a class="local">'Exertional myalgia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> should be continued during pregnancy and breastfeeding. (See <a class="local">'Pregnancy'</a> above and <a class="local">'Breastfeeding'</a> above.)</p><p></p><p class="headingAnchor" id="H112966088"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Peter M Rosenberg, MD, and Stephen E Goldfinger, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med 1972; 287:1302.</a></li><li><a class="nounderline abstract_t">Zemer D, Revach M, Pras M, et al. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med 1974; 291:932.</a></li><li><a class="nounderline abstract_t">Dinarello CA, Wolff SM, Goldfinger SE, et al. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med 1974; 291:934.</a></li><li><a class="nounderline abstract_t">Goldstein RC, Schwabe AD. Prophylactic colchicine therapy in familial Mediterranean fever. A controlled, double-blind study. Ann Intern Med 1974; 81:792.</a></li><li><a class="nounderline abstract_t">Wright DG, Wolff SM, Fauci AS, Alling DW. Efficacy of intermittent colchicine therapy in familial Mediterranean fever. Ann Intern Med 1977; 86:162.</a></li><li><a class="nounderline abstract_t">Hentgen V, Grateau G, Stankovic-Stojanovic K, et al. Familial Mediterranean fever in heterozygotes: are we able to accurately diagnose the disease in very young children? Arthritis Rheum 2013; 65:1654.</a></li><li><a class="nounderline abstract_t">Ben-Zvi I, Krichely-Vachdi T, Feld O, et al. Colchicine-free remission in familial Mediterranean fever: featuring a unique subset of the disease-a case control study. Orphanet J Rare Dis 2014; 9:3.</a></li><li><a class="nounderline abstract_t">Aviel YB, Rawan S, Fahoum S, et al. Discontinuation of Colchicine Therapy in Children With Familial Mediterranean Fever. J Rheumatol 2021; 48:1732.</a></li><li><a class="nounderline abstract_t">Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 2016; 75:644.</a></li><li><a class="nounderline abstract_t">Mor A, Shinar Y, Zaks N, et al. Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum 2005; 35:57.</a></li><li><a class="nounderline abstract_t">Livneh A, Zemer D, Langevitz P, et al. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum 1994; 37:1804.</a></li><li><a class="nounderline abstract_t">Zemer D, Livneh A, Langevitz P. Reversal of the nephrotic syndrome by colchicine in amyloidosis of familial Mediterranean fever. Ann Intern Med 1992; 116:426.</a></li><li><a class="nounderline abstract_t">Livneh A, Zemer D, Siegal B, et al. Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. Nephron 1992; 60:418.</a></li><li><a class="nounderline abstract_t">Polat A, Acikel C, Sozeri B, et al. Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever--a randomized controlled noninferiority trial. Arthritis Res Ther 2016; 18:85.</a></li><li class="breakAll">Gloperba (colchicine oral solution) US prescribing information version January 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210942s000lbl.pdf (Accessed on January 14, 2020).</li><li><a class="nounderline abstract_t">Paschke S, Weidner AF, Paust T, et al. Technical advance: Inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments. J Leukoc Biol 2013; 94:1091.</a></li><li><a class="nounderline abstract_t">Leung YY, Yao Hui LL, Kraus VB. Colchicine--Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 2015; 45:341.</a></li><li><a class="nounderline abstract_t">Van Gorp H, Saavedra PH, de Vasconcelos NM, et al. Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation. Proc Natl Acad Sci U S A 2016; 113:14384.</a></li><li><a class="nounderline abstract_t">Ter Haar N, Lachmann H, Özen S, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013; 72:678.</a></li><li><a class="nounderline abstract_t">Zemer D, Pras M, Sohar E, et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986; 314:1001.</a></li><li><a class="nounderline abstract_t">Saatci U, Bakkaloglu A, Ozen S, Besbas N. Familial Mediterranean fever and amyloidosis in children. Acta Paediatr 1993; 82:705.</a></li><li><a class="nounderline abstract_t">Sayarlioglu H, Erkoc R, Sayarlioglu M, et al. Successful treatment of nephrotic syndrome due to FMF amyloidosis with azathioprine: report of three Turkish cases. Rheumatol Int 2006; 27:197.</a></li><li><a class="nounderline abstract_t">Sevillano ÁM, Hernandez E, Gonzalez E, et al. Anakinra induces complete remission of nephrotic syndrome in a patient with familial mediterranean fever and amyloidosis. Nefrologia 2016; 36:63.</a></li><li><a class="nounderline abstract_t">Simsek C, Karatas M, Tatar E, et al. The efficacy of interleukin-1 antagonist drugs in combination with colchicine in patients with FMF-AA with colchicine resistance after kidney transplantation: A study with histopathologic evidence. Clin Transplant 2021; 35:e14309.</a></li><li><a class="nounderline abstract_t">Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum 2009; 38:411.</a></li><li><a class="nounderline abstract_t">Ehrenfeld M, Levy M, Margalioth EJ, Eliakim M. The effects of long-term colchicine therapy on male fertility in patients with familial Mediterranean fever. Andrologia 1986; 18:420.</a></li><li><a class="nounderline abstract_t">Bremner WJ, Paulsen CA. Colchicine and testicular function in man. N Engl J Med 1976; 294:1384.</a></li><li><a class="nounderline abstract_t">Haimov-Kochman R, Ben-Chetrit E. The effect of colchicine treatment on sperm production and function: a review. Hum Reprod 1998; 13:360.</a></li><li><a class="nounderline abstract_t">Lidar M, Scherrmann JM, Chetrit A, et al. Clinical, genetic, pharmacokinetic and socioeconomical characterization of colchicine nonresponsiveness in FMF (abstract). Clin Exp Rheumatol 2003; 29 (Suppl 26):88.</a></li><li><a class="nounderline abstract_t">Butbul Aviel Y, Tatour S, Gershoni Baruch R, Brik R. Colchicine as a therapeutic option in periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome. Semin Arthritis Rheum 2016; 45:471.</a></li><li class="breakAll">Peters, RS. Non-response to daily colchicine attack suppression in familial Mediterranean fever. Proceedings, 1st International Conference on FMF, Jerusalem, Israel 1997. p.8.</li><li><a class="nounderline abstract_t">Ben-Chetrit E, Aamar S. About colchicine compliance, resistance and virulence. Clin Exp Rheumatol 2009; 29(Suppl 5):S1.</a></li><li><a class="nounderline abstract_t">Özen S, Sag E, Ben-Chetrit E, et al. Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. Rheumatology (Oxford) 2021; 60:3799.</a></li><li><a class="nounderline abstract_t">Lidar M, Scherrmann JM, Shinar Y, et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 2004; 33:273.</a></li><li><a class="nounderline abstract_t">Niel E, Scherrmann JM. Colchicine today. Joint Bone Spine 2006; 73:672.</a></li><li><a class="nounderline abstract_t">Tufan A, Babaoglu MO, Akdogan A, et al. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol 2007; 34:1540.</a></li><li><a class="nounderline abstract_t">Druyan A, Giat E, Livneh A, et al. Effect of interleukin-1 inhibition in a cohort of patients with colchicine-resistant familial Mediterranean fever treated consecutively with anakinra and canakinumab. Clin Exp Rheumatol 2021; 39 Suppl 132:75.</a></li><li><a class="nounderline abstract_t">Atas N, Eroglu GA, Sodan HN, et al. Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients. Clin Exp Rheumatol 2021; 39 Suppl 132:30.</a></li><li><a class="nounderline abstract_t">Gül A, Ozdogan H, Erer B, et al. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther 2015; 17:243.</a></li><li><a class="nounderline abstract_t">Brik R, Butbul-Aviel Y, Lubin S, et al. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study. Arthritis Rheumatol 2014; 66:3241.</a></li><li><a class="nounderline abstract_t">van der Hilst JCh, Moutschen M, Messiaen PE, et al. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics 2016; 10:75.</a></li><li><a class="nounderline abstract_t">De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med 2018; 378:1908.</a></li><li><a class="nounderline abstract_t">Ozen S, Ben-Cherit E, Foeldvari I, et al. Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. Ann Rheum Dis 2020; 79:1362.</a></li><li><a class="nounderline abstract_t">Ben-Zvi I, Kukuy O, Giat E, et al. Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 2017; 69:854.</a></li><li><a class="nounderline abstract_t">Ugurlu S, Ergezen B, Egeli BH, et al. Anakinra treatment in patients with familial Mediterranean fever: a single-centre experience. Rheumatology (Oxford) 2021; 60:2327.</a></li><li><a class="nounderline abstract_t">Marko L, Shemer A, Lidar M, et al. Anakinra for colchicine refractory familial Mediterranean fever: a cohort of 44 patients. Rheumatology (Oxford) 2021; 60:2878.</a></li><li><a class="nounderline abstract_t">Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 2012; 157:533.</a></li><li><a class="nounderline abstract_t">Seyahi E, Ozdogan H, Celik S, et al. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol 2006; 24:S99.</a></li><li><a class="nounderline abstract_t">Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR. Infliximab treatment of Familial Mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheumatol 2004; 10:134.</a></li><li><a class="nounderline abstract_t">Fujikawa K, Migita K, Tsukada T, et al. Interleukin-6 targeting therapy in familial Mediterranean fever. Clin Exp Rheumatol 2013; 31:150.</a></li><li><a class="nounderline abstract_t">Akgul O, Kilic E, Kilic G, Ozgocmen S. Efficacy and safety of biologic treatments in Familial Mediterranean Fever. Am J Med Sci 2013; 346:137.</a></li><li><a class="nounderline abstract_t">Haj-Yahia S, Ben-Zvi I, Lidar M, Livneh A. Familial Mediterranean fever (FMF)-response to TNF-blockers used for treatment of FMF patients with concurrent inflammatory diseases. Joint Bone Spine 2021; 88:105201.</a></li><li><a class="nounderline abstract_t">Tunca M, Tankurt E, Akbaylar Akpinar H, et al. The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study. Br J Rheumatol 1997; 36:1005.</a></li><li><a class="nounderline abstract_t">Tunca M, Akar S, Soytürk M, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double-blind, placebo-controlled trial. Clin Exp Rheumatol 2004; 22:S37.</a></li><li><a class="nounderline abstract_t">Tweezer-Zaks N, Rabinovich E, Lidar M, Livneh A. Interferon-alpha as a treatment modality for colchicine- resistant familial Mediterranean fever. J Rheumatol 2008; 35:1362.</a></li><li><a class="nounderline abstract_t">Calguneri M, Apras S, Ozbalkan Z, et al. The efficacy of continuous interferon alpha administration as an adjunctive agent to colchicine-resistant familial Mediterranean fever patients. Clin Exp Rheumatol 2004; 22:S41.</a></li><li><a class="nounderline abstract_t">Langevitz P, Livneh A, Zemer D, et al. Seronegative spondyloarthropathy in familial Mediterranean fever. Semin Arthritis Rheum 1997; 27:67.</a></li><li><a class="nounderline abstract_t">Sakallioglu O, Duzova A, Ozen S. Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever. Clin Exp Rheumatol 2006; 24:435.</a></li><li><a class="nounderline abstract_t">Ehrenfeld M, Brzezinski A, Levy M, Eliakim M. Fertility and obstetric history in patients with familial Mediterranean fever on long-term colchicine therapy. Br J Obstet Gynaecol 1987; 94:1186.</a></li><li><a class="nounderline abstract_t">Ben-Chetrit E, Ben-Chetrit A, Berkun Y, Ben-Chetrit E. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res (Hoboken) 2010; 62:143.</a></li><li><a class="nounderline abstract_t">Diav-Citrin O, Shechtman S, Schwartz V, et al. Pregnancy outcome after in utero exposure to colchicine. Am J Obstet Gynecol 2010; 203:144.e1.</a></li><li><a class="nounderline abstract_t">Berkenstadt M, Weisz B, Cuckle H, et al. Chromosomal abnormalities and birth defects among couples with colchicine treated familial Mediterranean fever. Am J Obstet Gynecol 2005; 193:1513.</a></li><li><a class="nounderline abstract_t">Sotskiy PO, Sotskaya OL, Hayrapetyan HS, et al. Infertility Causes and Pregnancy Outcome in Patients With Familial Mediterranean Fever and Controls. J Rheumatol 2021; 48:608.</a></li><li><a class="nounderline abstract_t">Herscovici T, Merlob P, Stahl B, et al. Colchicine use during breastfeeding. Breastfeed Med 2015; 10:92.</a></li><li><a class="nounderline abstract_t">Ben-Chetrit E, Scherrmann JM, Levy M. Colchicine in breast milk of patients with familial Mediterranean fever. Arthritis Rheum 1996; 39:1213.</a></li></ol></div><div id="topicVersionRevision">Topic 2574 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4636899" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Colchicine for familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4606109" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A controlled trial of colchicine in preventing attacks of familial mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4606353" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Colchicine therapy for familial mediterranean fever. A double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4611296" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prophylactic colchicine therapy in familial Mediterranean fever. A controlled, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/319724" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Efficacy of intermittent colchicine therapy in familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23508419" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Familial Mediterranean fever in heterozygotes: are we able to accurately diagnose the disease in very young children?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24401676" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Colchicine-free remission in familial Mediterranean fever: featuring a unique subset of the disease-a case control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33993110" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Discontinuation of Colchicine Therapy in Children With Familial Mediterranean Fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26802180" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : EULAR recommendations for the management of familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16084225" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Evaluation of disease severity in familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7986228" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1736782" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Reversal of the nephrotic syndrome by colchicine in amyloidosis of familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1584316" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27055417" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever--a randomized controlled noninferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27055417" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever--a randomized controlled noninferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23901122" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Technical advance: Inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26228647" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Colchicine--Update on mechanisms of action and therapeutic uses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27911804" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22753383" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3515182" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8374224" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Familial Mediterranean fever and amyloidosis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16944160" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Successful treatment of nephrotic syndrome due to FMF amyloidosis with azathioprine: report of three Turkish cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26409501" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Anakinra induces complete remission of nephrotic syndrome in a patient with familial mediterranean fever and amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33813772" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The efficacy of interleukin-1 antagonist drugs in combination with colchicine in patients with FMF-AA with colchicine resistance after kidney transplantation: A study with histopathologic evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18973929" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Colchicine update: 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3752545" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The effects of long-term colchicine therapy on male fertility in patients with familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1264178" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Colchicine and testicular function in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9557838" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The effect of colchicine treatment on sperm production and function: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical, genetic, pharmacokinetic and socioeconomical characterization of colchicine nonresponsiveness in FMF (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26315860" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Colchicine as a therapeutic option in periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26315860" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Colchicine as a therapeutic option in periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis (PFAPA) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : About colchicine compliance, resistance and virulence</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33331943" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14978665" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17067838" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Colchicine today.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17610314" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34369359" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of interleukin-1 inhibition in a cohort of patients with colchicine-resistant familial Mediterranean fever treated consecutively with anakinra and canakinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34251317" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26337145" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25049046" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27110096" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29768139" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32571870" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27860460" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33295622" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Anakinra treatment in patients with familial Mediterranean fever: a single-centre experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34144604" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Anakinra for colchicine refractory familial Mediterranean fever: a cohort of 44 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23070486" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17067437" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17043487" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Infliximab treatment of Familial Mediterranean fever and its effect on secondary AA amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24064027" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Interleukin-6 targeting therapy in familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23276893" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Efficacy and safety of biologic treatments in Familial Mediterranean Fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33932573" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Familial Mediterranean fever (FMF)-response to TNF-blockers used for treatment of FMF patients with concurrent inflammatory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9376975" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15515782" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18528960" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Interferon-alpha as a treatment modality for colchicine- resistant familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15515783" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The efficacy of continuous interferon alpha administration as an adjunctive agent to colchicine-resistant familial Mediterranean fever patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9355205" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Seronegative spondyloarthropathy in familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16956436" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3426990" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Fertility and obstetric history in patients with familial Mediterranean fever on long-term colchicine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20191511" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20579964" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pregnancy outcome after in utero exposure to colchicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16202748" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Chromosomal abnormalities and birth defects among couples with colchicine treated familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33004533" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Infertility Causes and Pregnancy Outcome in Patients With Familial Mediterranean Fever and Controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25646562" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Colchicine use during breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8670333" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Colchicine in breast milk of patients with familial Mediterranean fever.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
